Bicara Therapeutics Inc. (NASDAQ: BCAX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock.
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
Bicara Therapeutics Inc. (NASDAQ: BCAX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $13.01 price target on the stock.
Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth [Yahoo! Finance]